Shanghai Hile Bio-tech (SHG:603718) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Hile Bio-tech (603718)
Shanghai Hile Bio-tech (SHG:603718) has a market capitalization of $299.54 Million (CN¥2.05 Billion) as of June 17, 2026. Listed on the SHG stock exchange, this China-based company holds position #14969 globally and #4457 in its home market, demonstrating a -4.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Hile Bio-tech's stock price CN¥3.14 by its total outstanding shares 651904700 (651.90 Million). Review how much debt does Shanghai Hile Bio-tech carry to assess the company's total debt and financial obligations.
Shanghai Hile Bio-tech Market Cap History: 2015 to 2026
Shanghai Hile Bio-tech's market capitalization history from 2015 to 2026. Data shows change from $2.09 Billion to $299.54 Million (-14.55% CAGR).
Shanghai Hile Bio-tech Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Hile Bio-tech's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.10x
Shanghai Hile Bio-tech's market cap is 3.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.68 Billion | $343.34 Million | $85.54 Million | 4.88x | 19.59x |
| 2017 | $1.04 Billion | $303.65 Million | $113.74 Million | 3.43x | 9.16x |
| 2018 | $1.20 Billion | $254.57 Million | $21.30 Million | 4.71x | 56.29x |
| 2019 | $1.21 Billion | $277.99 Million | $12.15 Million | 4.36x | 99.84x |
| 2020 | $1.20 Billion | $259.13 Million | $8.93 Million | 4.61x | 133.91x |
| 2021 | $1.45 Billion | $347.29 Million | $53.86 Million | 4.18x | 26.94x |
| 2022 | $931.14 Million | $299.99 Million | $121.61 Million | 3.10x | 7.66x |
| 2023 | $1.02 Billion | $240.72 Million | $62.87 Million | 4.24x | 16.25x |
| 2024 | $659.17 Million | $271.04 Million | $171.18 Million | 2.43x | 3.85x |
| 2025 | $581.90 Million | $187.87 Million | -$311.44 Million | 3.10x | N/A |
Competitor Companies of 603718 by Market Capitalization
Companies near Shanghai Hile Bio-tech in the global market cap rankings as of June 17, 2026.
Key companies related to Shanghai Hile Bio-tech by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Shanghai Hile Bio-tech Historical Marketcap From 2015 to 2026
Between 2015 and today, Shanghai Hile Bio-tech's market cap moved from $2.09 Billion to $ 299.54 Million, with a yearly change of -14.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥299.54 Million | -48.52% |
| 2025 | CN¥581.90 Million | -11.72% |
| 2024 | CN¥659.17 Million | -35.48% |
| 2023 | CN¥1.02 Billion | +9.72% |
| 2022 | CN¥931.14 Million | -35.82% |
| 2021 | CN¥1.45 Billion | +21.37% |
| 2020 | CN¥1.20 Billion | -1.47% |
| 2019 | CN¥1.21 Billion | +1.18% |
| 2018 | CN¥1.20 Billion | +15.14% |
| 2017 | CN¥1.04 Billion | -37.87% |
| 2016 | CN¥1.68 Billion | -19.93% |
| 2015 | CN¥2.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Shanghai Hile Bio-tech was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $299.54 Million USD |
| MoneyControl | $299.54 Million USD |
| MarketWatch | $299.54 Million USD |
| marketcap.company | $299.54 Million USD |
| Reuters | $299.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry… Read more